46th week of 2014 patent applcation highlights part 38 |
Patent application number | Title | Published |
20140335076 | Humanized Monoclonal Antibodies to Hepatocyte Growth Factor - The present invention is directed toward a humanized neutralizing monoclonal antibody to hepatocyte growth factor, a pharmaceutical composition comprising same, and methods of treatment comprising administering such a pharmaceutical composition to a patient. | 2014-11-13 |
20140335077 | Compositions and Methods for the Treatment of Cancer Using IGF-IR Antagonists and MAPK/ERK Inhibitors - The present invention relates generally to the field of cancer therapy. More specifically the present invention relates a combination therapy where IGF-1R antagonists are combined with MAPK/ERK pathway inhibitors. The present invention relates to a therapeutic combination comprising an IGF-1R antagonist and a MAPK/ERK pathway inhibitor, and to methods for the production of an anti-cancer effect in a patient. The present invention relates to: a therapeutic combination comprising an IGF-1R antagonist and a MAPK/ERK pathway inhibitor; a combination product comprising an IGF-1R antagonist and a MAPK/ERK pathway inhibitor, a kit of parts comprising an IGF-1R antagonist and a MAPK/ERK pathway inhibitor; use of a therapeutic combination, combination product or kit of parts in the treatment of cancer; a method of treating cancer comprising administering the therapeutic combination, combination product or kit of parts to a patient. | 2014-11-13 |
20140335078 | Use Of Complement Inhibitors To Treat Ocular Diseases - The present invention relates to the treatment of ocular diseases and conditions by administering a complement pathway inhibitor, particularly an alternative pathway inhibitor. Ocular diseases include age-related macular degeneration, diabetic retinopathy, and ocular angiogenesis. One embodiment comprises the administration of an anti-Factor D antibody in the form of a whole antibody, a Fab fragment or a single domain antibody. Other complement component inhibitors that may be useful in the present method include Factor H or inhibitors that block the action of properdin, factor B, factor Ba, factor Bb, C2, C2a, C3a, C5, C5a, C5, C6, C7, C8, C9, or C5b-9. | 2014-11-13 |
20140335079 | SOLENOPSIN AND DERIVATIVES, THERAPEUTIC COMPOSITIONS, AND METHODS RELATED THERETO - This disclosure relates to solenopsin derivatives, pharmaceutical compositions, and therapeutic uses related thereto. In certain embodiments, the disclosure relates to compounds of the following formula: | 2014-11-13 |
20140335080 | ESTER DERIVATIVES OF ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE - Compounds having a structure of Structure I: | 2014-11-13 |
20140335081 | Treatment For Rheumatoid Arthritis - Treatment of rheumatoid arthritis (RA) to provide clinical benefit in patients, including decrease in DAS28-CRP by more than 1.2 and/or improvement determined by ACR20, ACR50 or ACR70, comprising administering therapeutic antibody mavrilimumab or other inhibitor targeted to Tyr-Leu-Asp-Phe-Gln motif of granulocyte/macrophage colony stimulating factor receptor alpha (GM-CSFRα). Use of GM-CSFRα inhibitors such as mavrilimumab to enhance clinical benefit in RA patients receiving stable dose of DMARDs, particularly methotrexate. | 2014-11-13 |
20140335082 | COMBINATION THERAPY COMPRISING AN MMP-14 BINDING PROTEIN - Proteins that bind to matrix metalloproteinase 14, combination therapies with such proteins and methods of using such proteins are described. | 2014-11-13 |
20140335083 | METHODS OF TREATMENT AND PREVENTION OF EYE DISEASES - The present invention provides compositions and methods useful for treating and preventing neovascular AMD by inhibition of CCR3. The compositions and methods are useful for treating and preventing diseases and disorders such as but not limited to, neovascular AMD | 2014-11-13 |
20140335084 | ANTIBODY FORMULATION - The present invention relates to an anti-CD44 monoclonal antibody formulation, a process for the preparation of said formulation and uses thereof. | 2014-11-13 |
20140335085 | FUSION PROTEIN - A new fusion protein which can specifically suppress the autoantibodies, which can effectively prevent or treat the autoimmune disease of autoantibody type, and which can be expressed in an amount sufficient for industrial production. A fusion protein, characterized in that, a protein (X) containing a site recognized by autoantibodies which are a cause of the autoimmune disease of autoantibody type is connected to a protein (A) containing a fragment of the antibody heavy chain constant region which exhibits the antibody-dependent cellular cytotoxicity with a linker peptide (L) consisting of one or more amino acid(s), wherein the protein (X), the linker peptide (L) and the protein (A) are connected in this order by means of peptide bond from N terminal to C terminal. | 2014-11-13 |
20140335086 | MODIFIED HEAT SHOCK PROTEIN-ANTIGENIC PEPTIDE COMPLEX - The present invention relates to methods for purifying immunogenic, prophylactically and therapeutically effective complexes of modified heat shock proteins noncovalently associated with antigenic peptides of cancer or infected cells. The claimed methods comprise the constructing of a nucleotide sequence encoding a secretable modified heat shock protein, expressing the sequence in an appropriate host cell, recovering the immunogenic complexes from the cell culture and the cells, and purifying the immunogenic complexes by affinity chromatography. Large amounts of such immunogenic complexes can be obtained by large-scale culturing of host cells containing the genetic sequence. The complexes can be used as a vaccine to elicit specific immune responses against cancer or infected cells, and to treat or prevent cancer or infectious diseases. | 2014-11-13 |
20140335087 | ASPARTYL-TRNA SYNTHETASE-FC CONJUGATES - The present invention provides aspartyl-tRNA synthetase and Fc region conjugate polypeptides (DRS-Fc conjugates), such as DRS-Fc fusion proteins, compositions comprising the same, and methods of using such conjugates and compositions for treating or diagnosing a variety of conditions. The DRS-Fc conjugates of the invention have improved controlled release properties, stability, half-life, and other pharmacokinetic and biological properties relative to corresponding, unmodified DRS polypeptides. | 2014-11-13 |
20140335088 | Antibodies and Vaccines for Use in Therapeutic and Diagnostic Methods for Alpha-Synuclein-Related Disorders - Methods of treating or delaying onset of a neurodegenerative disorder with α-synuclein pathology in an individual comprise administering an antibody which is produced from a stabilized soluble α-synuclein oligomer and capable of binding a stabilized soluble α-synuclein oligomer, the stabilized soluble α-synuclein oligomer having a lower formation rate to a non-soluble aggregated form than a non-stabilized soluble oligomer of the α-synuclein. The antibody has been collected from a non-human animal to which stabilized soluble α-synuclein oligomer had been administered or has been produced by hybridoma technology, phage display, ribosome display, mammalian cell display or bacterial display, and the disorder with α-synuclein pathology is characterized by deposition of Lewy bodies and Lewy neurites or is selected from the group consisting of Parkinson's disease (PD), dementia with Lewy bodies (DLB), the Lewy body variant of Alzheimer's disease, and multiple system atrophy (MSA). | 2014-11-13 |
20140335089 | ANTIGEN-BINDING MOLECULE FOR PROMOTING ELIMINATION OF ANTIGENS - The present inventors created antigen-binding molecules containing an antigen-binding domain and an Fcγ-receptor-binding domain, wherein the molecules have human-FcRn-binding activity in an acidic pH range condition, the antigen-binding domain changes the antigen-binding activity of the antigen-binding molecules depending on the ion-concentration condition, and the Fcγ receptor-binding domain has higher binding activity to the Fcγ receptor in a neutral pH range condition than an Fc region of a native human IgG in which the sugar chain bound at position 297 (EU numbering) is a fucose-containing sugar chain. | 2014-11-13 |
20140335090 | THERAPEUTIC AGENT FOR CANCER, AND METHOD FOR DETERMINING PROGNOSIS OF CANCER - Disclosed are a novel therapeutic agent for cancer such as esophageal squamous cell carcinoma, a method for predicting the prognosis of cancer, and a method for detecting, or predicting the prognosis of, cancer such as esophageal squamous cell carcinoma using a sample that can be collected less invasively. The therapeutic agent for cancer comprises as an effective component an antibody that undergoes antigen-antibody reaction with FGFRL1 to suppress the growth of cancer cells, or an antigen-binding fragment thereof. The method for predicting the prognosis of cancer comprises investigating the expression level of FGFRL1 in a cancer tissue separated from a living body, and, in this method, a high expression level of FGFRL1 indicates poor prognosis. The method for detecting cancer comprises measuring FGFRL1 or a fragment thereof extracted from a body tissue, or FGFRL1 or a fragment thereof in blood separated from a living body, and, in this method, a higher concentration of FGFRL1 or the fragment thereof contained therein than the concentration of FGFRL1 or the fragment thereof in the tissue or blood of a healthy individual indicates the presence of cancer. | 2014-11-13 |
20140335091 | ANTI-GLUCAGON RECEPTOR ANTIBODIES AND METHODS OF USE THEREOF - The present invention provides antagonizing antibodies that bind to glucagon receptor and methods of using same. The anti-glucagon receptor antibodies can be used therapeutically to lower glucose levels in blood, and can be in the prevention and/or treatment of glucose-related disorders, including diabetes, hyperglycemia, hyperinsulinemia, impaired fasting glucose, impaired glucose tolerance, dyslipidemia, or metabolic syndrome. | 2014-11-13 |
20140335092 | COMPOSITIONS AND METHODS FOR IMMUNIZATION AGAINST DRUG RESISTANT ACINETOBACTER BAUMANNII - The present invention provides vaccine compositions comprising OmpA, or antigenic fragments thereof, and related methods of active immunization against | 2014-11-13 |
20140335093 | PD-1 Antibodies and PD-L1 Antibodies and Uses Thereof - The invention relates to PD-1 antibodies and PD-L1 antibodies and uses thereof. | 2014-11-13 |
20140335094 | MAMMALIAN CYTOKINES; RELATED REAGENTS AND METHODS - Purified genes encoding cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using said reagents and diagnostic kits are also provided. | 2014-11-13 |
20140335095 | COMPOSITIONS AND METHODS RELATED TO PROTEIN A (SPA) ANTIBODIES AS AN ENHANCER OF IMMUNE RESPONSE - The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a | 2014-11-13 |
20140335096 | ANTI-GLUCAGON ANTIBODIES AND USES THEREOF - Provided are monoclonal antibodies, or antigen-binding fragments thereof, that bind to glucagon. These antibodies are useful in immunoassays of glucagon levels, and/or in vivo, ex vivo or in vitro immunochemical and other imaging methods for detecting glucagon levels, and for diagnostic, prognostic and predictive purposes, and for optimizing therapeutic regimens in patients in which glucagon signaling is implicated in pathogenesis. | 2014-11-13 |
20140335097 | EXPRESSION VECTOR - The present invention provides an expression vector for cell-surface expression of proteins. | 2014-11-13 |
20140335098 | METHOD OF ISOLATING HUMAN ANTIBODIES - Provided is a novel method of isolating and producing human antibodies with desired specificity from human B cells. In particular, a method of isolating human antibodies from memory B cells obtained from patients which suffer from a disease which is caused by or involves activation of the immune system, for example autoimmune and inflammatory disorders is described. | 2014-11-13 |
20140335099 | THERAPEUTIC HUMAN ANTI-IL-1R1 MONOCLONAL ANTIBODY - Antibodies that interact with interleukin-1 receptor type 1 (IL-1R1) are described. Methods of treating IL-1 mediated diseases by administering a pharmaceutically effective amount of antibodies to IL-1R1 are described. Methods of detecting the amount of IL-1R1 in a sample using antibodies to IL-1R1 are described. | 2014-11-13 |
20140335100 | THERAPY-ENHANCING GLUCAN - This invention provides a composition comprising an effective amount of glucan capable of enhancing efficacy of antibodies. This invention further provides the above compositions and a pharmaceutically acceptable carrier. This invention also provides a method for treating a subject with cancer comprising administrating the above-described composition to the subject. This invention provides a composition comprising effective amount of glucan capable of enhancing efficacy of vaccines. This invention also provides a method of treating a subject comprising administrating the above pharmaceutical composition to the subject. This invention provides a composition comprising effective amount of glucan capable of enhancing efficacy of natural antibodies. This invention provides a composition comprising effective amount of glucan capable of enhancing host immunity. This invention also provides a composition comprising effective amount of glucan capable of enhancing the action of an agent in preventing tissue rejection. | 2014-11-13 |
20140335101 | NANOBODIES AGAINST TUMOR NECROSIS FACTOR-ALPHA - The present invention relates to improved Nanobodies™ against Tumor Necrosis Factor-alpha (TNF-alpha), as well as to polypeptides comprising or essentially consisting of one or more of such Nanobodies. The invention also relates to nucleic acids encoding such Nanobodies and polypeptides; to methods for preparing such Nanobodies and polypeptides; to host cells expressing or capable of expressing such Nanobodies or polypeptides; to compositions comprising such Nanobodies, polypeptides, nucleic acids or host cells; and to uses of such Nanobodies, such polypeptides, such nucleic acids, such host cells or such compositions, in particular for prophylactic, therapeutic or diagnostic purposes, such as the prophylactic, therapeutic or diagnostic purposes. | 2014-11-13 |
20140335102 | IN SILICO AFFINITY MATURATION - Methods are disclosed for increasing the binding affinity of binding proteins using in silico affinity maturation. | 2014-11-13 |
20140335103 | CYTOKINE RECEPTORS ASSOCIATED WITH MYELOGENOUS HAEMATOLOGICAL PROLIFERATIVE DISORDERS AND USES THEREOF - The disclosure relates to methods and compositions effective in the diagnosis, prognosis and treatment of human hematopoietic cancers. In particular, the disclosure provides tumor-associated genes that encode for cytokine receptors that are differentially expressed in hematopoietic tumor cells of myeloid origin compared with other cells, e.g., normal stem cells. | 2014-11-13 |
20140335104 | Methods of Detecting Cells with a Disrupted Cell Membrane, Cells Infected with A Pathogen, Dying Cells or Dead Cells - The present invention relates to methods of modulating the uptake and/or clearance of cells with a disrupted cell membrane, cells infected with a pathogen, dying cells or dead cells, or a portion thereof, which can be used to treat and/or prevent diseases such as cancer, autoimmunity and infections. The present invention also relates to methods of modulating antigen recognition, processing and/or presentation, as well as immune responses to material derived from cells with a disrupted cell membrane, cells infected with a pathogen, dying cells or dead cells, or a portion thereof. The present invention further relates to methods of detecting cells with a disrupted cell membrane, cells infected with a pathogen, dying cells or dead cells, or a portion thereof. | 2014-11-13 |
20140335105 | METHODS OF GENERATING HYPER INOS EXPRESSING CELLS AND USES THEREOF - A method of generating a hyper iNOS expressing cell includes administering to a myeloid derived cell an amount of a PPARγ agonist and an IL-6/STAT3 signaling pathway antagonist effective to substantially inhibit STAT3 activation in the cell and administering an inflammatory insult to the cell to stimulate hyper iNOS expression from the cell. | 2014-11-13 |
20140335106 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR TREATING CANCER - A method of treating cancer by inhibiting expression of ubiquitin associated and SH3 domain containing B (UBASH3B) gene or by inhibiting the activity of UBASH3B protein or a functional variant thereof. | 2014-11-13 |
20140335107 | ANTI-CD79B ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE - The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same. | 2014-11-13 |
20140335108 | UTILITY OF INSULIN-LIKE 6 (INSL6) FOR THE TREATMENT OF AUTOIMMUNE DISEASES - The present invention is directed to compositions and methods to treat an autoimmune disease in a subject, comprising an insulin-like 6 (Insl6) agent, such as an Insl6 polypeptide or variant or fragment thereof, or a nucleic acid encoding Insl6 poly peptide or variant or fragment thereof. Aspects of the present invention relate to use of Insl6 agents to reduce T-regulatory (Treg) cells in the subject and to reduce pro-inflammatory cytokines in a subject with an autoimmune disease such as a muscle autoimmune disease. The present invention also relates to methods and kits for the treatment of autoimmune diseases in a subject, and methods to diagnose a subject with an autoimmune disease such as myositis. | 2014-11-13 |
20140335109 | COMBINATION OF INOTUZUMAB OZOGAMICIN AND TORISEL FOR THE TREATMENT OF CANCER - The present invention relates to a therapeutic method for the treatment of cancer that comprises the use of a combination of inotuzumab ozogamicin (CMC-544) and temsirolimus. The enhanced antitumor of the combination therapy is particularly useful for patient population that are recalcitrant to inotuzumab ozogamicin or temsirolimus therapy, relapse after treatment with inotuzumab ozogamicin or temsirolimus or where enhanced antitumor effect reduces toxicities associated with treatment using inotuzumab ozogamicin or temsirolimus. | 2014-11-13 |
20140335110 | LASER-BASED VACCINE ADJUVANTS - The invention is directed to a vaccine for generating an enhanced immune response in a subject previously exposed to non-destructive laser radiation, as compared to an immune response in a subject previously non-exposed to non-destructive laser radiation. The invention is also directed to use of a composition comprising a vaccine for use in combination with non-destructive laser radiation for generating an enhanced immune response from a subject, as compared to an immune response without the use of laser radiation. The laser exposure acts as an adjuvant for the vaccine, increasing the efficacy and/or potency of the vaccine. | 2014-11-13 |
20140335111 | VACCINES AND IMMUNOTHERAPEUTICS USING IL-28 AND COMPOSITIONS AND METHODS OF USING THE SAME - Compositions, recombinant vaccines and live attenuated pathogens comprising one or more isolated nucleic acid molecules that encode an immunogen in combination with an isolated nucleic acid molecule that encodes IL-28 or a functional fragment thereof are disclosed. Methods of inducing an immune response in an individual against an immunogen, using such compositions are disclosed. | 2014-11-13 |
20140335112 | NOVEL DOUBLE-STRANDED RIBONUCLEIC ACIDS WITH RUGGED PHYSICO-CHEMICAL STRUCTURE AND HIGHLY SPECIFIC BIOLOGIC ACTIVITY - A novel form of Rugged dsRNA with a unique composition and physical characteristics was identified with high specificity of binding to TLR3, which conveys an important range of therapeutic opportunities. Unlike the previous known antiviral Ampligen® (poly I, poly C12,U) the new and improved form (poly I, poly C | 2014-11-13 |
20140335113 | FACTOR H FOR TRANSPLANTATION - The present invention provides a method for preventing or inhibiting allograft rejection by a recipient of that allograft by treating the recipient with a composition comprising Factor H (FH). The invention also encompasses methods in which the recipient is also administered one or more immunosuppressants in addition to the Factor H. | 2014-11-13 |
20140335114 | HYR1 AS A TARGET FOR ACTIVE AND PASSIVE IMMUNIZATION AGAINST CANDIDA - The invention features HYR1 as a vaccine target and as a prophylactic strategy for combating disseminated candidiasis. | 2014-11-13 |
20140335115 | SUPPRESSORS OF MATURE T CELLS - Disclosed herein is a viral polypeptide and homologs thereof that inhibit an immune response, particularly the response of memory and effector CD4 | 2014-11-13 |
20140335116 | AVOIDING NARCOLEPSY RISK IN INFLUENZA VACCINES - The invention provides influenza vaccines and methods which improve the safety of influenza vaccines further, in particular in relation to the risk of causing narcolepsy in adjuvanted vaccines. | 2014-11-13 |
20140335117 | Identification and Attenuation of the Immunosuppressive Domains in Fusion Proteins of Enveloped RNA Viruses - The present invention relates to enveloped RNA viruses. The invention in particular relates to the generation of superior antigens for mounting an immune response by first identifying then mutating the immunosuppressive domains in fusion proteins of enveloped RNA viruses resulting in decreased immunosuppressive properties of viral envelope proteins from the viruses. | 2014-11-13 |
20140335118 | SYNTHETIC PEPTIDE-BASED MARKER VACCINE AND DIAGNOSTIC SYSTEM FOR EFFECTIVE CONTROL OF PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME (PRRS) - A peptide-based marker vaccine against Porcine Reproductive and Respiratory Syndrome (PRRS) and a set of immunodiagnostic tests for the prevention, monitoring and control of Porcine Reproductive and Respiratory Syndrome Virus (PRRSV) are disclosed. Vaccine formulations according to various embodiments of the invention contain a mixture of peptides derived from PRRSV GP2, GP3, GP4, or GP5 proteins; each peptide individually contains a B cell PRRSV neutralizing/receptor binding epitope which is individually linked to an artificial T helper epitope for enhancement of the respective peptide's immunogenicity; and which can be supplemented with a mixture of peptides representing the T helper epitopes derived from the PRRSV GP4, GP5, M and Nucleocapsid proteins to provide cell mediated immunity. Such viral peptide compositions are prepared in an acceptable delivery system as vaccine formulations and can provide cross protection of PRRSV antibody free pigs from infection upon PRRSV challenge. | 2014-11-13 |
20140335119 | POLYPEPTIDE DERIVED FROM gp41, A VACCINE COMPOSITION COMPRISING SAID POLYPEPTIDE, AND USES FOR TREATING AN INFECTION BY AN HIV VIRUS IN AN INDIVIDUAL - The present invention relates to the field of the in vitro diagnosis of the progression status of an infection of an individual with a virus belonging to the family of the Human Immunodeficiency Viruses (HIV) as well as with the therapeutical treatment of this infectious disease. The invention also relates to immunological compounds and vaccine compositions comprising a polypeptide derived from gp41. | 2014-11-13 |
20140335120 | DUAL DELIVERY SYSTEM FOR HETEROLOGOUS ANTIGENS - Provided herein are recombinant | 2014-11-13 |
20140335121 | FIMBRIAE TYPE OF PROPHYROMONAS GULAE - The present invention has as its object to provide a process for determining the degree of pathogenicity of infecting bacterial strains in the case of canine periodontal disease. | 2014-11-13 |
20140335122 | COMPOUND, EXTRACT ISOLATED FROM ANTRODIA CAMPHORATE, AND METHOD USING THE SAME - Disclosed is a compound isolated from | 2014-11-13 |
20140335123 | Food Composition and Uses for Diabetes - The present invention provides a composition to promote healthy weight and reduce diabetic complications. The composition provides biologically active ingredients that are combined in a food and provide dietary fiber, trace minerals and phytonutrients, wherein the composition may be used alone or in combination with other foods in a method for improving health. | 2014-11-13 |
20140335124 | Recombinant Trivalent Vaccine Against Human Influenza - Recombinant trivalent vaccine against human influenza contains recombinant adenoviral vector with a nucleotide sequence which encodes at least one antigen of influenza virus strain, while non-replicating nanoparticles are used as adenoviral vectors based on genome of human adenovirus of serotype 5, capable of expressing the haemagglutinin of influenza virus which induce human immune response to influenza virus, wherein the vaccine contains composition of three kinds of non-replicating nanoparticles, each of which carries different influenza hemagglutinin genes, further comprises immunostimulant and formulating buffer. In this solution the influenza virus hemagglutinin genes are: H1, H3, HB and any other recommended by the World Health Organization at the time of production. Formulating buffer is added to the composition to achieve a total volume of 0.5 ml and a vaccine dose of 0.5 ml. | 2014-11-13 |
20140335125 | ATTENUATED AND ADAPTED STRAIN OF PSEUDOMONAS FOR DELIVERING ANTIGENS - A process for obtaining an adapted strain of | 2014-11-13 |
20140335126 | V1V2 IMMUNOGENS - The present invention relates, in general, to human immunodeficiency virus (HIV), and in particular to a vaccine for HIV-1 and to methods of making and using same. | 2014-11-13 |
20140335127 | SYSTEM AND METHOD FOR THE PRODUCTION OF RECOMBINANT GLYCOSYLATED PROTEINS IN A PROKARYOTIC HOST - A system and a method for the production of recombinant N-glycosylated target proteins. The system comprises a prokaryotic organism (e.g. | 2014-11-13 |
20140335128 | ADENOVIRAL VECTOR-BASED MALARIA VACCINES - The invention provides a method of inducing an immune response against malaria in a mammal. The method comprises intramuscularly administering to a mammal a composition comprising a pharmaceutically acceptable carrier and either or both of (a) a first adenoviral vector comprising a nucleic acid sequence encoding a | 2014-11-13 |
20140335129 | NON-DIGESTIBLE OLIGOSACCHARIDES FOR ORAL INDUCTION OF TOLERANCE AGAINST DIETARY PROTEINS - Compositions and methods for providing infant nutrition with partially hydrolysed proteins and non-digestible oligosaccharides for use in induction of oral tolerance against native dietary proteins. | 2014-11-13 |
20140335130 | AMINO ACID SUPPLEMENTATION FOR A HEALTHY MICROBIOTA ECOSYSTEM - The present invention pertains to a nutritional composition for reconstituting an optimal healthy microbiota ecosystem in humans or animals. In particular, the present invention relates to an ingestible carrier containing specific amino acids designed to favor the growth of bacteria favorable to individuals health or for reducing the risk of developing deleterious events. The invention also pertains to the use of specific amino acids for reconstituting an optimal healthy microbiota ecosystem in humans or animals, in particular in infants, critically ill patients, in the case of chronic diseases or any stresses impacting the gut and in elderly people. | 2014-11-13 |
20140335131 | PROBIOTIC PREVENTION AND TREATMENT OF COLON CANCER - Methods are provided herein for preventing, delaying the onset of or reducing the progression of colorectal tumorigenesis in a subject identified as at risk of colorectal tumorigenesis, comprising adjusting the composition of gut microbiota in the subject via administering to the subject a composition comprising | 2014-11-13 |
20140335132 | BINDING DRUGS WITH NANOCRYSTALLINE CELLULOSE (NCC) - This invention describes nanocrystalline cellulose (NCC) for use as a drug delivery excipient. NCC binds significant quantities of water soluble, ionizable drugs, e.g., tetratcycline and doxorubicin, which are released rapidly over a one day period. A surfactant such as cetyl trimethylammonium bromide (CTAB) can bind to the surface of NCC and increase the zeta potential in a concentration-dependent manner from −55 to 0 mV. NCC with CTAB modified surfaces can bind significant quantities of the hydrophobic drugs such as anticancer drugs docetaxel, paclitaxel and etoposide. These drugs were released in a controlled manner over a 2-day period. The NCC-CTAB nanocomplexes were found to bind to KU-7 cells and evidence of cellular uptake was observed. | 2014-11-13 |
20140335133 | LOW-OIL PHARMACEUTICAL EMULSION COMPOSITIONS COMPRISING PROGESTOGEN - Described are sterile, ready-to-use, pharmaceutical oil-in-water emulsion compositions for parenteral administration comprising:
| 2014-11-13 |
20140335135 | PHARMACEUTICAL COMPOSITION - Sustained release formulations of triptorelin are provided. | 2014-11-13 |
20140335136 | COMPOSITIONS FOR MINIMIZING SKIN IMPERFECTIONS - Disclosed herein are compositions comprising, in a cosmetically acceptable medium, a silicone material comprising concave and/or annular particles; hydrophobic silica aerogel particles; fillers chosen from platelet type fillers and silica particles other than hydrophobic silica aerogel particles; a fatty substance chosen from fatty alcohols and fatty acids; an emulsifying agent and a thickening agent, wherein the silica material, hydrophobic silica aerogel particles and fillers are present in a total amount of greater than 4% by weight, based on the total weight of the composition. Also disclosed herein is a process for reducing the visibility of imperfections on skin, comprising applying the composition onto the skin. | 2014-11-13 |
20140335137 | Topical DNA Repair Composition - Provided herein are topical compositions for repairing sun damaged skin and topical sunscreen compositions for both preventing and repairing sun damage. | 2014-11-13 |
20140335138 | MICROCAPSULES COMPRISING BLACK PIGMENTS - Monolayered microcapsules comprising a black pigment and cosmetic formulations comprising them are provided for use particularly in mascara and eye liner formulations. The black pigment may be carbon black, black iron oxide, or both. | 2014-11-13 |
20140335139 | LONG LASTING BREATH MINT - A long lasting breath mint including a carrier and a flavorant, wherein the carrier includes at least one of a high viscosity cellulose ether and a low viscosity cellulose either and an alginate. The carrier forms a gel upon contact with saliva. A tablet is placed in the mouth of user, whereupon the tablet is wetted with saliva. A surface of the tablet is converted to a gel resulting in a tablet having an outer gel layer and a core. The gel serves as an adhesive for adhering the tablet to mouth structure. The gel slows exposure of the core to moisture and also slows diffusion of flavorant into the mouth of the user with the gel resulting in a breath mint having an extremely long life prior to complete dissolution, e.g., greater than 30 minutes or longer. | 2014-11-13 |
20140335140 | NATURAL VOLATILE PLANT OILS TO REPEL ARTHROPODS - A composition and method for the controlled release of natural plant oils (essential oils) from a wax matrix to repel insects, arachnids, and other arthropods. | 2014-11-13 |
20140335141 | LAYERED MANUFACTURING UTILIZING FOAM AS A SUPPORT AND MULTIFUNCTIONAL MATERIAL FOR THE CREATION OF PARTS AND FOR TISSUE ENGINEERING - One aspect of the invention provides a solid freeform fabrication method of creating a three-dimensional article built at least in part from scaffolding layers. The method includes: providing a scaffolding material; providing a supporting material in a shape of a foamy layer; and contacting the scaffolding material with the foamy layer to form at least one scaffolding layer and thereby creating the three dimensional article. Another aspect of the invention provides a three-dimensional article manufactured by using the methods described herein. Yet another embodiment provides a three-dimensional article including: a scaffolding material and a supporting material in a shape of a foamy layer coupled to the scaffolding material. | 2014-11-13 |
20140335142 | METHOD OF SURFACE TREATMENT OF AN IMPLANT, AN IMPLANT TREATED BY SAID METHOD AND AN ELECTROLYTE SOLUTION FOR USE IN SAID METHOD - A method of surface treatment of at least part of an electro-conductive surface of an implant, in particular an orthopaedic or a dental implant is described which permits the simultaneous, electrochemical deposition of a therapeutic agent and a calcium phosphate coating in a combined single-step deposition process. The method involves the preparation of an electrolyte solution containing calcium and phosphorus ions and a therapeutic agent, preferably in combination with a complexing agent such that the resulting complex has a net positive charge. This electrolyte solution is then used in an electrochemical deposition process to produce a calcium phosphate coating incorporating the therapeutic agent on the electro-conductive surface of the implant Preferably, the therapeutic agent comprises metal ions, for example silver ions, and the complexing agent comprises an ammine complex. Also provided are an implant treated by the described method and an electrolyte solution for use in the described method. | 2014-11-13 |
20140335143 | Polymer Blends For Drug Delivery Stent Matrix With Improved Thermal Stability - Various embodiments of the present invention generally relate to a polymer blend composition used for coating a medical device that exhibits improved thermal stability. The invention also encompasses implantable medical devices coated the aforementioned coating. | 2014-11-13 |
20140335144 | TISSUE SCAFFOLDS DERIVED FROM FORESTOMACH EXTRACELLULAR MATRIX - The present invention pertains to the development of Extracellular Matrix (ECM) scaffolds derived from the forestomach of a ruminant. Such scaffolds are useful in many clinical and therapeutic applications, including wound repair, tissue regeneration, and breast reconstruction. In addition, the present invention features methods of isolating ECM scaffolds from mammalian organs, including but not limited to the ruminant forestomach. The invention further features laminated ECM scaffolds containing a polymer positioned between individual ECM sheets. The polymer may optionally contain bioactive molecules to enhance the functionality of the scaffold. | 2014-11-13 |
20140335145 | BIOMATERIALS AND IMPLANTS FOR ENHANCED CARTILAGE FORMATION, AND METHODS FOR MAKING AND USING THEM - The invention provides products of manufacture, e.g., biomaterials and implants, for cartilage maintenance and/or formation in-vivo, in-vitro, and ex-vivo, using nanotechnology, e.g., using nanotube, nanowire, nanopillar and/or nanodepots configured on surface structures of the products of manufacture. | 2014-11-13 |
20140335146 | GROWTH FACTOR ANCHORING TYPE BONE GRAFT MATERIAL, METHOD FOR PRODUCING GROWTH FACTOR ANCHORING TYPE BONE GRAFT MATERIAL, KIT FOR PRODUCING GROWTH FACTOR ANCHORING TYPE BONE GRAFT MATERIAL, AND METHOD FOR FORMING BONE - Provided is a growth factor anchoring type bone graft material, wherein a bone graft substrate exposing at least a collagen fiber is bound to a collagen-binding-site-containing growth factor which contains a growth factor receptor agonist peptide and a collagen-binding peptide. The same can be produced by mixing a bone graft substrate and a collagen-binding-site-containing growth factor which contains a growth factor receptor agonist peptide and a collagen-binding peptide, and is also superior in osteogenic ability. | 2014-11-13 |
20140335147 | REGENERATION AID FOR BONE DEFECTS - The invention relates to a molded part for supporting bone regeneration, in particular the regeneration of a jawbone or jawbone section in a mammal, preferably a human, wherein the molded part is suitable for applying to the jawbone and has a coating having a composition comprising at least one collagen, a granular material, and hyaluronic acid or a hyaluronic acid derivative. The invention further relates to a granular material that can be used in the coating, to a method for producing the granular material, and to the use of the molded part. | 2014-11-13 |
20140335148 | BIOACTIVE SUBSTANCE-CONTAINING NANOFIBERS AND USES THEREOF - An ultrafine fiber comprises a ceramic-based fibrous body and a biologically active substance encapsulated in the body, substantially encapsulated in the body, or surface-attached to the body. In an example, an ultrafine fiber comprises a core comprising a biologically active substance and a ceramic-based shell surrounding or substantially surrounding the core. | 2014-11-13 |
20140335149 | WOUND-HEALING PROMOTING MATERIAL - The object of the present invention is to provide a means for utilizing cells that have effects on wound healing as wound-healing promoting materials by efficiently concentrating such cells within a short period of time. The present invention provides a wound-healing promoting material which comprises a sheet-like porous body having on its surface at least leukocytes and/or platelets, a method for producing the same, a device for producing the same, and a method for treating wound sites using the same. | 2014-11-13 |
20140335150 | THERAPEUTIC PATCH - The invention relates to a topical patch comprising a therapeutic compound-impermeable backing layer, a self-adhesive matrix based on polysiloxanes and containing capsaicin or a therapeutic compound analogous to capsaicin, and a protective film to be removed before use, in which the matrix contains liquid microreservoirs based on an amphiphilic solvent, in which the therapeutic compound is present in completely dissolved form and the concentration of the therapeutic compound in the microreservoir droplets is below the saturation concentration. The invention furthermore relates to a process for its production and its use in the treatment of neuropathic pain. | 2014-11-13 |
20140335151 | PATCH CONTAINING NON-STEROIDAL ANTI-INFLAMMATORY DRUG - The present invention is directed to a patch containing a non-steroidal anti-inflammatory drug including an adhesive layer composed of a transdermal preparation on a support, the transdermal preparation including a) 10 to 40% by weight of a non-aqueous base material based on the total weight of the transdermal preparation, b) 1 to 10% by weight of a non-steroidal anti-inflammatory drug based on the total weight of the transdermal preparation, and c) a polyethylene glycol component composed of 0.3 to 5% by weight of a low molecular weight polyethylene glycol based on the total weight of the transdermal preparation, and 1 to 10% by weight of a high molecular weight polyethylene glycol based on the total weight of the transdermal preparation. | 2014-11-13 |
20140335152 | METHODS AND COMPOSITIONS FOR ENHANCING THE UPTAKE OF THERAPEUTIC AGENTS BY TARGET CELLS - The present invention relates to a new use of a known medicament. Specifically, the invention relates to methods and compositions for enhancing the therapeutic efficacy of a therapeutic agent by increasing the uptake of the therapeutic agent by target cells, and in particular relates to a pharmaceutical composition comprising a regulating agent of lipid raft/caveolae-dependent endocytic pathway and some therapeutic agents, such as anti-tumor agents. The invention also relates to a method for screening a regulating agent of lipid raft/caveolae-dependent endocytic pathway capable of enhancing the therapeutic efficacy of anti-tumor agents. | 2014-11-13 |
20140335153 | THIN FILM WITH HIGH LOAD OF ACTIVE INGREDIENT - A method of preparing a thin film, the method comprising: (a) mixing a lipid, emulsifier, and solvent to provide a uniform first mixture; (b) contacting an active ingredient with the uniform first mixture to provide a thickened second mixture; (c) contacting a binder with the thickened second mixture to provide a slurry; and (d) hot extruding, casting, and condensing the slurry to provide the thin film; or cooling, shearing, mixing, casting, and condensing the slurry to provide the thin film. | 2014-11-13 |
20140335154 | METHODS AND FORMULATIONS TO ACHIEVE TUMOR TARGETED DOUBLE STRANDED RNA MEDIATED CELL DEATH - A composition having double stranded ribonucleic acid (dsRNA) molecules is provided. The composition induces tumor cell death or suppresses tumor growth. The double stranded RNA molecules contain equal to or less than 15 base pairs. Methods for delivery of the composition are also disclosed. | 2014-11-13 |
20140335155 | COMPOSITION FOR IMPROVING SKIN CONDITIONS, CONTAINING EXTRACELLULAR DOMAIN OF HUMAN BONE MORPHOGENETIC PROTEIN RECEPTOR 1a AS ACTIVE INGREDIENT - The present invention provides a composition for improving skin conditions, containing the extracellular domain of human bone morphogenetic protein receptor 1a as an active ingredient. The present invention contains the extracellular domain of human bone morphogenetic protein receptor 1a as an active ingredient inside a nanoliposome comprising hydrogenated lecithin as a constituent component, and the particle size is 50-250 nm. The composition of the present invention reduces wrinkles and alleviates atopic dermatitis. In addition, the present invention provides a method for improving skin conditions, comprising the step of administering a composition containing the extracellular domain of human bone morphogenetic protein receptor 1a as an active ingredient to a subject. | 2014-11-13 |
20140335156 | NANOPARTICLE-ASSISTED ULTRASOUND FOR CANCER THERAPY - Methods for killing cancer cells and treating cancer in a subject by exposing the cells to nanoparticles, and irradiating with a focused, low to medium power ultrasound. The nanoparticles can be gold, iron oxide, copper, silver, polystyrene, PEG, or liposome nanoparticles. The nanoparticles can have a cancer drug attached, such as an antibody-based cancer drug. | 2014-11-13 |
20140335157 | CATIONIC LIPID HAVING IMPROVED INTRACELLULAR KINETICS - The present invention relates to a compound represented by the formula (1) | 2014-11-13 |
20140335158 | Protein and Nucleic Acid Delivery Vehicles, Components and Mechanisms Thereof - Complex viruses are assembled from simple protein subunits by sequential and irreversible assembly. During genome packaging in bacteriophages, a powerful molecular motor assembles at the special portal vertex of an empty prohead to initiate packaging. An aspect of the invention relates to the phage T4 packaging machine being highly promiscuous, translocating DNA into finished phage heads as well as into proheads. Single motors can force exogenous DNA into phage heads at the same rate as into proheads and phage heads undergo repeated initiations, packaging multiple DNA molecules into the same head. This shows that the phage DNA packaging machine has unusual conformational plasticity, powering DNA into an apparently passive capsid receptacle, including the highly stable virus shell, until it is full. These features allow for the design of a novel class of nanocapsid delivery vehicles. | 2014-11-13 |
20140335159 | Biodegradable Nanoparticles as Novel Hemoglobin-Based Oxygen Carriers and Methods of Using the Same - Compositions of matter and methods for making, storing and administering artificial blood substitutes. Artificial blood substitutes may have oxygen carriers that encapsulate an oxygen-binding compound in a polymer vesicle. Oxygen-binding compounds may include hemoglobin, myoglobin, or other oxygen binding compounds having characteristics similar to hemoglobin. Oxygen carriers may include nanoparticles, polymers and/or polymersomes comprising of poly(ethylene oxide)-block-poly(ε-caprolactone) (PEO-b-PCL) and related diblock copolymers of poly(ethylene oxide)-block-poly(γ-methyl ε-caprolactone) (PEO-b-PMCL). The oxygen carriers may have tunable oxygen-binding capacities, uniform and appropriately small size distributions, and human bloodlike viscosities and oncotic properties. | 2014-11-13 |
20140335160 | Biodegradable Nanoparticles as Novel Hemoglobin-Based Oxygen Carriers and Methods of Using the Same - Compositions of matter and methods for making, storing and administering artificial blood substitutes. Artificial blood substitutes may have oxygen carriers that encapsulate an oxygen-binding compound in a polymer vesicle. Oxygen-binding compounds may include hemoglobin, myoglobin, or other oxygen binding compounds having characteristics similar to hemoglobin. Oxygen carriers may include nanoparticles, polymers and/or polymersomes comprising of poly(ethylene oxide)-block-poly(ε-caprolactone) (PEO-b-PCL) and related diblock copolymers of poly(ethylene oxide)-block-poly(γ-methyl ε-caprolactone) (PEO-b-PMCL). The oxygen carriers may have tunable oxygen-binding capacities, uniform and appropriately small size distributions, and human bloodlike viscosities and oncotic properties. | 2014-11-13 |
20140335161 | Compositions and Methods for the Diagnosis and Therapy of BCL2-Associated Cancers - Provided are methods and compositions for the treatment of cancers associated with overexpression of a BCL2 gene and/or gene product in a subject, and methods and compositions for the improvement of anti-cancer therapy, such as chemotherapy and radiation therapy. Also provided are methods for determining the efficacy of a cancer therapy in a subject, methods for diagnosing cancer, methods for assessing patient prognosis, and methods for inducing apoptosis of a cell. | 2014-11-13 |
20140335162 | PHARMACEUTICAL COMPOSITION FOR TREATMENT OF ALLERGIC REACTIONS - The invention relates to a pharmaceutical composition made of one or more preparations and comprising a physiologically effective dose of at least one IL-4 and/or IL-13 inhibitor and at least one allergene, and a matrix, wherein at least the inhibitor is solved or embedded, or whereon at least the inhibitor is coated or adsorbed, wherein the matrix is selected as to enable prolonged release of the inhibitor. | 2014-11-13 |
20140335163 | TARGETED IDURONATE-2-SULFATASE COMPOUNDS - The present invention is related to a compound that includes a lysosomal enzyme and a targeting moiety, for example, where compound is a fusion protein including iduronate-2-sulfatase and Angiopep-2. In certain embodiments, these compounds, owning to the presence of the targeting moiety can crossing the blood-brain barrier or accumulate in the lysosome more effectively than the enzyme alone. The invention also features methods for treating lysosomal storage disorders (e.g., mucopolysaccharidosis Type II) using such compounds. | 2014-11-13 |
20140335164 | LIPOSOMES AND ITS PRODUCTION METHOD - The present invention is the use of conjugated peptide sequences for inclusion in liposomal membranes. The combination can be done with folic acid or with an antibody of folic acid receptor coupled to N-terminal peptide. The presence of these peptides conjugated to liposomal formulations allows the targeting and subsequent release of therapeutic agents and/or imaging agents to cells expressing folic acid receptor. | 2014-11-13 |
20140335165 | SUSTAINED-RELEASE NUCLEIC ACID MATRIX COMPOSITIONS - There are provided compositions for extended release of a nucleic acid agent, comprising a lipid-saturated matrix formed with a biodegradable polymer. Also provided are methods of producing the matrix compositions and methods for using the matrix compositions to provide controlled release of the nucleic acid agent. | 2014-11-13 |
20140335166 | Methods of Making and Using Nano Scale Particles - A method for preparing a phospholipid delivery system encapsulating one or more bio-affecting compounds, includes the steps of solubilizing a heterogeneous phospholipid mixture into an organic solvent to form a concentrated formulation of phospholipids, in which the phospholipids include a charged phospholipid species and mixing the concentrated formulation with an aqueous solution having at least one bio-affecting compound. A method of using a phospholipid delivery system encapsulating at least one bio-affecting compound for the administration to an individual in need thereof is also disclosed. | 2014-11-13 |
20140335167 | Consumer Products Comprising Silane-Modified Oils - A consumer product comprises silane-modified oil comprising a hydrocarbon chain selected from the group consisting of: a saturated oil, an unsaturated oil, and mixtures thereof; and at least one hydrolysable silyl group covalently bonded to the hydrocarbon chain. The silane-modified oil is substantially stripped of substantially stripped of reagents prior to formulating into the consumer products, such that the silane-modified oil comprises less than about 10%, preferably less than about 5%, preferably less than about 1%, preferably less than about 0.1%, by weight of said silane-modified oil, of residual reagent comprising silicon. | 2014-11-13 |
20140335168 | THERAPEUTIC AGENT PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE - Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade to release the drug into the bloodstream to produce a therapeutic effect. The preparation can be operably coupled to delivery means having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract. | 2014-11-13 |
20140335169 | Peptide Pharmaceutical for Oral Delivery - Acid-containing oral pharmaceutical compositions are provided wherein the pharmaceutical active agents are peptide compounds (i.e., those that include a plurality of amino acids and at least one peptide bond in their molecular structures). Certain barrier layers and/or particulate coated acid are used to reduce any adverse interactions that might otherwise occur between the acid of the compositions and other components of the composition. Use of these barrier layers and/or use of particulate coated acid is believed to promote a more simultaneous release of the components of the composition than is achieved by prior art acid-protection techniques, thus enhancing, and making more consistent, the bioavailability of the active peptide compounds. | 2014-11-13 |
20140335170 | Reduced Mass Metformin Formulations - The present invention relates to metformin extended release (XR) formulations with improved compactability to provide reduced mass tablets, granulations, and capsules. | 2014-11-13 |
20140335171 | Stable Formulations of Antiplatelet Agents, Omega-3 Fatty Acids and Amylose In Soft Gelatin Capsules - The invention discloses stable formulations of acetylsalicylic acid or salts thereof, omega-3 fatty acids and amylose in soft gelatin capsules. | 2014-11-13 |
20140335172 | OPHTHALMOLOGICAL RINSING AGENT AND METHODS THEREFOF - Disclosed herein is a novel rinsing agent, which may be suitable for use in surgical, and, in particular, ophthalmological procedures. The rinsing agent may by employed to remove emulsified oil droplets from the eye cavity. Also disclosed is a method for effectively removing emulsified silicone oil droplets remaining in the eye cavity after ophthalmological procedures using the disclosed rinsing agent in order to prevent the development of long-term complications associated with the emulsified oil droplets. | 2014-11-13 |
20140335173 | RELEASE CAPSULES, MANUFACTURE AND USES THEREOF - The present invention relates to novel release capsules, particularly for protecting moisture-sensitive materials, particularly compositions for production of chlorine dioxide. The invention also relates to methods of manufacture of such release capsules, uses of such release capsules, and products comprising them. | 2014-11-13 |
20140335174 | DRY-COATED TABLET CONTAINING TEGAFUR, GIMERACIL AND OTERACIL POTASSIUM - The present invention provides a dry-coated tablet comprising: an inner core containing, as active ingredients, (a) tegafur, (b) gimeracil, and (c) oteracil potassium; and an outer shell. | 2014-11-13 |
20140335175 | Extended Release Tablet Formulation Containing Pramipexole or a Pharmaceutically Acceptable Salt Thereof - An extended release tablet formulation comprising pramipexole or a pharmaceutically acceptable salt thereof in a matrix comprising at least one water swelling polymer other than pregelatinized starch. | 2014-11-13 |
20140335176 | DISINTEGRANT-FREE DELAYED RELEASE DOXYLAMINE AND PYRIDOXINE FORMULATION AND PROCESS OF MANUFACTURING - The present invention relates to a delayed release pharmaceutical composition containing doxylamine succinate and pyridoxine HCl for treatment of nausea and vomiting during pregnancy. More specifically, the present invention concerns a disintegrant-free delayed release pharmaceutical composition for oral administration comprising a core and an enteric coating, wherein said core comprising: a) at least one pharmaceutically active ingredient, and b) at least one pharmaceutically acceptable excipient, wherein said composition provides an in vitro drug release profile of about 80% of active ingredient dissolved within 20 minutes as measured by USP Type II apparatus and also a manufacturing process of said pharmaceutical composition. | 2014-11-13 |